Literature DB >> 23933910

The synergistic therapeutic effect of hepatocyte growth factor and granulocyte colony-stimulating factor on pulmonary hypertension in rats.

Yinghua Guo1, Longxiang Su, Yinghui Li, Na Guo, Lixin Xie, Dong Zhang, Xiaojun Zhang, Hongxia Li, Guizhi Zhang, Yajuan Wang, Changting Liu.   

Abstract

Pulmonary arterial hypertension (PAH) is characterized by a progressive increase in pulmonary arterial pressure and vascular resistance. Despite advances in therapy for PAH, its treatment and prognosis remain poor. We aimed to investigate whether the transplantation of bone marrow mesenchymal stem cells (MSCs) overexpressing hepatocyte growth factor (HGF), alone or in combination with granulocyte colony-stimulating factor (G-CSF), attenuates the development of experimental monocrotaline (MCT)-induced PAH. Three weeks after MCT administration, rats were divided into the following groups: (1) untreated (PAH); (2) HGF treated; (3) MSCs administered; (4) HGF-MSCs treated; and (5) HGF-MSCs plus G-CSF treated. After 3 weeks, hemodynamic changes, histomorphology, and angiogenesis were evaluated. To elucidate the molecular mechanisms of vascular remodeling and angiogenesis, serum levels of transforming growth factor (TGF)-β and endothelin-1 (ET-1) were measured, and the gene and protein expression levels of vascular cell adhesion molecule-1 (VCAM-1) and matrix metalloproteinase-9 (MMP-9) were determined. Compared with the PAH, MSC, and G-CSF groups, the HGF and HGF+G-CSF groups exhibited significantly reduced right ventricular hypertrophy and mean pulmonary arterial pressure (P < 0.05). Histologically, vessel muscularization or thickening and collagen deposition were also significantly decreased (P < 0.05). The number of vessels in the HGF+G-CSF group was higher than that in the other groups (P < 0.05). The TGF-β and ET-1 concentrations in the plasma of pulmonary hypertensive rats were markedly lower in the HGF and HGF+G-CSF groups (P < 0.05). Furthermore, HGF induced the expression of VCAM-1, and HGF treatment together with G-CSF synergistically stimulated MMP-9 expression. Transplanted HGF-MSCs combined with G-CSF potentially offer synergistic therapeutic benefit for the treatment of PAH.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23933910     DOI: 10.1007/s00380-013-0395-1

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  43 in total

1.  Circulating endothelial precursors: mystery, reality, and promise.

Authors:  S Rafii
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

Review 2.  Endothelial progenitor cells: new hope for a broken heart.

Authors:  Paul E Szmitko; Paul W M Fedak; Richard D Weisel; Duncan J Stewart; Michael J B Kutryk; Subodh Verma
Journal:  Circulation       Date:  2003-06-24       Impact factor: 29.690

3.  The matrix revolutions: matrix metalloproteinase, vasculogenesis, and ischemic tissue repair.

Authors:  Marie-Ange Renault; Douglas W Losordo
Journal:  Circ Res       Date:  2007-03-30       Impact factor: 17.367

4.  The HGF/c-Met axis synergizes with G-CSF in the mobilization of hematopoietic stem/progenitor cells.

Authors:  Ali Jalili; Neeta Shirvaikar; Leah A Marquez-Curtis; A Robert Turner; Anna Janowska-Wieczorek
Journal:  Stem Cells Dev       Date:  2010-08       Impact factor: 3.272

5.  Granulocyte colony-stimulating factor prevents progression of monocrotaline-induced pulmonary arterial hypertension in rats.

Authors:  Hidekazu Maruyama; Shigeyuki Watanabe; Taizo Kimura; Jingyan Liang; Toshiro Nagasawa; Masafumi Onodera; Kazutaka Aonuma; Iwao Yamaguchi
Journal:  Circ J       Date:  2007-01       Impact factor: 2.993

6.  Hepatocyte growth factor mobilizes and recruits hematopoietic progenitor cells into liver through a stem cell factor-mediated mechanism.

Authors:  Fumihito Tajima; Hiroyuki Tsuchiya; Kenichi Nishikawa; Motoyuki Kataoka; Ichiro Hisatome; Goshi Shiota
Journal:  Hepatol Res       Date:  2010-06-14       Impact factor: 4.288

7.  Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease.

Authors:  Yidan D Zhao; David W Courtman; Yupu Deng; Lakshmi Kugathasan; Qiuwang Zhang; Duncan J Stewart
Journal:  Circ Res       Date:  2005-02-03       Impact factor: 17.367

8.  The remodeling of connexin in the hypertrophied right ventricular in pulmonary arterial hypertension and the effect of a dual ET receptor antagonist (bosentan).

Authors:  Xiao-Yan Tan; Jian-Guo He
Journal:  Pathol Res Pract       Date:  2009-02-20       Impact factor: 3.250

Review 9.  Primary pulmonary hypertension.

Authors:  James R Runo; James E Loyd
Journal:  Lancet       Date:  2003-05-03       Impact factor: 79.321

10.  Treatment of myocardial ischemia with bone marrow-derived mesenchymal stem cells overexpressing hepatocyte growth factor.

Authors:  Hai-Feng Duan; Chu-Tse Wu; Dan-Li Wu; Ying Lu; Hong-Jun Liu; Xiao-Qin Ha; Qun-Wei Zhang; Hua Wang; Xiang-Xu Jia; Li-Sheng Wang
Journal:  Mol Ther       Date:  2003-09       Impact factor: 11.454

View more
  12 in total

1.  Non-suppressive regulatory T cell subset expansion in pulmonary arterial hypertension.

Authors:  Yoshiharu Sada; Yoshihiro Dohi; Sayuri Uga; Akifumi Higashi; Hiroki Kinoshita; Yasuki Kihara
Journal:  Heart Vessels       Date:  2015-08-29       Impact factor: 2.037

2.  Hepatocyte growth factor suppresses hypoxia/reoxygenation-induced XO activation in cardiac microvascular endothelial cells.

Authors:  Yingqian Zhang; Shunying Hu; Yundai Chen
Journal:  Heart Vessels       Date:  2014-07-26       Impact factor: 2.037

3.  Galectin-3 levels are associated with right ventricular functional and morphologic changes in pulmonary arterial hypertension.

Authors:  Brett E Fenster; Luis Lasalvia; Joyce D Schroeder; Jamey Smyser; Lori J Silveira; J Kern Buckner; Kevin K Brown
Journal:  Heart Vessels       Date:  2015-05-15       Impact factor: 2.037

4.  Pulmonary arterial hypertension induced by a novel method: Twice-intraperitoneal injection of monocrotaline.

Authors:  Wei Zhuang; Guili Lian; Bangbang Huang; Apang Du; Genfa Xiao; Jin Gong; Changsheng Xu; Huajun Wang; Liangdi Xie
Journal:  Exp Biol Med (Maywood)       Date:  2018-08-12

5.  Targeted delivery of pulmonary arterial endothelial cells overexpressing interleukin-8 receptors attenuates monocrotaline-induced pulmonary vascular remodeling.

Authors:  Jinyan Fu; Yiu-Fai Chen; Xiangmin Zhao; Judy R Creighton; Yuanyuan Guo; Fadi G Hage; Suzanne Oparil; Daisy D Xing
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-05-01       Impact factor: 8.311

Review 6.  Recent advances in the therapeutic efficacy of hepatocyte growth factor gene-modified mesenchymal stem cells in multiple disease settings.

Authors:  Hong-Fang Meng; Jide Jin; Hua Wang; Li-Sheng Wang; Chu-Tse Wu
Journal:  J Cell Mol Med       Date:  2022-08-03       Impact factor: 5.295

7.  Iron is associated with the development of hypoxia-induced pulmonary vascular remodeling in mice.

Authors:  Yoshiro Naito; Manami Hosokawa; Hisashi Sawada; Makiko Oboshi; Toshihiro Iwasaku; Yoshitaka Okuhara; Akiyo Eguchi; Koichi Nishimura; Yuko Soyama; Shinichi Hirotani; Toshiaki Mano; Masaharu Ishihara; Tohru Masuyama
Journal:  Heart Vessels       Date:  2016-06-16       Impact factor: 2.037

8.  Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib.

Authors:  Noriyuki Koyama; Kenichi Saito; Yuki Nishioka; Wataru Yusa; Noboru Yamamoto; Yasuhide Yamada; Hiroshi Nokihara; Fumiaki Koizumi; Kazuto Nishio; Tomohide Tamura
Journal:  BMC Cancer       Date:  2014-07-21       Impact factor: 4.430

9.  Effect of miR-29b on the Proliferation and Apoptosis of Pulmonary Artery Smooth Muscle Cells by Targeting Mcl-1 and CCND2.

Authors:  Juan Chen; Yanping Li; Yun Li; Lijian Xie; Jianyi Wang; Yongwei Zhang; Tingting Xiao
Journal:  Biomed Res Int       Date:  2018-01-31       Impact factor: 3.411

10.  Low plasma stem cell factor combined with high transforming growth factor-α identifies high-risk patients in pulmonary arterial hypertension.

Authors:  Habib Bouzina; Göran Rådegran
Journal:  ERJ Open Res       Date:  2018-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.